Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of migraine and other neurological disorders. The company's lead product candidate, STS101, is a novel, oral small molecule that is being developed for the acute treatment of migraine. STS101 has been shown to be effective in multiple clinical trials in patients with migraine, and the company is currently conducting a Phase 3 clinical trial to evaluate the efficacy and safety of STS101 in the acute treatment of migraine. Satsuma Pharmaceuticals also has a pipeline of other product candidates in development for the treatment of migraine and other neurological disorders.